Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.8922
+0.0406 (4.77%)
Jun 4, 2025, 2:05 PM - Market open
Ocugen Revenue
Ocugen had revenue of $1.48M in the quarter ending March 31, 2025, with 46.06% growth. This brings the company's revenue in the last twelve months to $4.52M, down -31.56% year-over-year. In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%.
Revenue (ttm)
$4.52M
Revenue Growth
-31.56%
P/S Ratio
52.67
Revenue / Employee
$47,600
Employees
95
Market Cap
260.55M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OCGN News
- 8 days ago - Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - GlobeNewsWire
- 26 days ago - Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress - GlobeNewsWire
- 2 months ago - Ocugen to Present at the 2025 Cell & Gene Meeting on the Med - GlobeNewsWire
- 2 months ago - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - GlobeNewsWire
- 3 months ago - Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript - Seeking Alpha